曲美他嗪治疗不稳定性心绞痛临床观察

Clinic outcome of patients with unstable angina pectoris treated with trimetazidine

目的探讨曲美他嗪治疗不稳定性心绞痛的临床疗效。方法40例不稳定性心绞痛病人随机分为对照组18例和治疗组22例,治疗组在常规处理的基础上,选用曲美他嗪20mg,每天3次,连续口服,疗程3周.结束后观察疗效以及治疗前后血脂、C反应蛋白、WBC的变化,并与对照组比较。结果治疗组总有效率95.45%,与对照组相比较有显著性差异(P<0.01);经治疗组治疗前后血脂、C反应蛋白与WBC对照,治疗组血清胆固醇、C反应蛋白、WBC显著下降(P<0.01);治疗组治疗前后及两组间心绞痛发作次数与持续时间有明显改善(P<0.01)。结论曲美他嗪可改善接受常规治疗的不稳定性心绞痛病人的临床表现。

Objective To investigate treated with trimetazidine. Methods the clinic outcome of patients with unstable 40 cases patients with UA were randomly divided control group （18 patients） and curing group （22 patients）. The patients of control angina pectoris into two groups, roup were cured with only regulart reatment but the patients of curing group were clealt with TMZ 20mg, rid qn in the basis of regulant treatment, the period of treatment was 3 weeks. The levels of serum blood -lipid.CRP and the number of WBC were tasted and compared 3 weeks later. Results The effective rate of curing group was 95.45 percent and there was significant difference between two groups （P〈0.01）. The levels of serum blood-lipid,CRP and the number of WBC in patients after TMZ in treatment were significantly lower than those in the patients before TMZ in treatment （P〈0.01） ：The attack times of angina pectoris and the periods of status anginosus were greatly improved in contrast with after and before TMZ in treatment （P〈0.01）.Conclusion Trimetazidine can bring about additional improvements in patients with unstable angina pectoris.